このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Viatris 将来の成長

Future 基準チェック /36

Viatrisの収益は年間1.6%で減少すると予測されていますが、年間利益は年間5.2%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に12.2% 10.9%なると予測されています。

主要情報

14.4%

収益成長率

20.8%

EPS成長率

Pharmaceuticals 収益成長	23.6%
収益成長率	-1.4%
将来の株主資本利益率	8.9%
アナリストカバレッジ	Good
最終更新日	25 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqGS:VTRS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	14,522	784	2,853	3,217	6
12/31/2025	14,464	667	3,136	2,632	7
12/31/2024	14,827	1,534	5,879	2,930	7
6/30/2024	15,239	-646	1,884	2,297	N/A
3/31/2024	15,361	-56	2,000	2,443	N/A
12/31/2023	15,427	55	2,325	2,800	N/A
9/30/2023	15,466	1,832	2,023	2,473	N/A
6/30/2023	15,602	1,854	2,045	2,508	N/A
3/31/2023	15,800	1,904	2,332	2,785	N/A
12/31/2022	16,263	2,079	2,510	2,953	N/A
9/30/2022	16,728	804	2,835	3,333	N/A
6/30/2022	17,187	761	3,035	3,550	N/A
3/31/2022	17,648	168	2,779	3,307	N/A
12/31/2021	17,886	-1,269	2,508	3,017	N/A
9/30/2021	17,168	-1,921	1,784	2,530	N/A
6/30/2021	15,604	-2,047	1,296	1,969	N/A
3/31/2021	13,757	-1,728	1,166	1,790	N/A
12/31/2020	11,946	-670	551	1,232	N/A
9/30/2020	11,514	266	1,539	1,882	N/A
6/30/2020	11,504	271	1,502	1,845	N/A
3/31/2020	11,624	63	1,687	2,135	N/A
12/31/2019	11,501	17	1,398	1,804	N/A
9/30/2019	11,387	48	1,022	1,753	N/A
6/30/2019	11,288	34	1,187	1,919	N/A
3/31/2019	11,245	240	789	1,680	N/A
12/31/2018	11,434	353	1,146	2,342	N/A
9/30/2018	11,594	546	1,270	2,201	N/A
6/30/2018	11,719	457	1,098	2,096	N/A
3/31/2018	11,873	717	N/A	2,234	N/A
12/31/2017	11,908	696	N/A	2,065	N/A
9/30/2017	11,937	869	N/A	1,919	N/A
6/30/2017	12,007	661	N/A	2,571	N/A
3/31/2017	11,605	533	N/A	2,420	N/A
12/31/2016	11,077	480	N/A	2,047	N/A
9/30/2016	10,300	257	N/A	2,350	N/A
6/30/2016	9,938	806	N/A	2,124	N/A
3/31/2016	9,749	805	N/A	1,822	N/A
12/31/2015	9,429	848	N/A	2,009	N/A
9/30/2015	9,021	842	N/A	1,483	N/A
6/30/2015	8,410	913	N/A	949	N/A
3/31/2015	7,876	870	N/A	1,014	N/A
12/31/2014	7,720	929	N/A	1,015	N/A
9/30/2014	7,445	920	N/A	1,306	N/A
6/30/2014	7,129	580	N/A	1,280	N/A
3/31/2014	6,993	633	N/A	1,287	N/A
12/31/2013	6,909	624	N/A	1,107	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VTRSは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: VTRS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: VTRS今後 3 年以内に収益を上げることが予想されます。

収益対市場: VTRSの収益は今後 3 年間で減少すると予想されています (年間-1.6% )。

高い収益成長: VTRSの収益は今後 3 年間で減少すると予測されています (年間-1.6% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VTRSの自己資本利益率は、3年後には低くなると予測されています ( 12.2 %)。

Viatris 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates increase by 11%

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Price target decreased to US$12.55

Consensus forecasts updated

Recent updates

Viatris Inc. to Report Q3, 2024 Results on Nov 07, 2024

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Viatris Inc. Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

Director notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter dividend of US$0.12 announced

Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024

Viatris Inc. Declares Quarterly Dividend, Payable on September 13, 2024

Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc. (NasdaqGS:VTRS).

Director recently sold US$3.6m worth of stock

Director notifies of intention to sell stock

Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope

Viatris Inc. to Report Q2, 2024 Results on Aug 08, 2024

IQuest Enterprises Private Limited acquired API operations of Viatris in India.

Viatris: Skeptics Proven Right Once Again

Chief Legal Officer recently sold US$928k worth of stock

First quarter dividend of US$0.12 announced

Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024

First quarter 2024 earnings: EPS misses analyst expectations

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).